The Effect of Alendronate Treatment on Bone Density and Bone Markers in Postmenopausal Osteoporosis
The objective of this blind, randomized controlled study was to evaluate effect of 12 months alendronate treatment on bone mineral density (BMD) and bone formation, resorption markers in postmenopausal osteoporotic women. Women with BMD values at least 2 standard deviations (SD) below BMD of adult p...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Yayinevi
2002-03-01
|
| Series: | Türk Osteoporoz Dergisi |
| Subjects: | |
| Online Access: | http://www.turkosteoporozdergisi.org/article_4172/The-Effect-Of-Alendronate-Treatment-On-Bone-Density-And-Bone-Markers-In-Postmenopausal-Osteoporosis |
| _version_ | 1797914901761490944 |
|---|---|
| author | S. Akı R. G. Gulbaba N. Eskiyurt |
| author_facet | S. Akı R. G. Gulbaba N. Eskiyurt |
| author_sort | S. Akı |
| collection | DOAJ |
| description | The objective of this blind, randomized controlled study was to evaluate effect of 12 months alendronate treatment on bone mineral density (BMD) and bone formation, resorption markers in postmenopausal osteoporotic women. Women with BMD values at least 2 standard deviations (SD) below BMD of adult premenopousal women were included in the study. Patients were randomized into two groups. The control group (n=ll2) received 500 mg daily elemental calcium, while the treatment group (n=l58) received 10 mg alendronate plus 500 mg daily elemental calcium for 12 months. Patient demographics were comparable in both groups before treatment. After 12 months, BMD of patients in alendronate group was increased significantly as compared to BMD before treatment and BMD in control group (p<0.001) . Increase in BMD was apparent in all measured sites but highest values were attained in the Ll-L4 region with 4.8 %. Bone formation and resorption parameters showed significant decrease in the 6 th and 12 th months of treatment as compared to control group and values before treatment (-23.1% to - 50.6 %). As a conclusion, twelve months treatment of alendronate (10 mg/day) in postmenopausal osteoporotic women causes a significant increase of BMD in all measurement sites, as compared to BMD values before treatment and BMD of control group. Likewise bone formation and resorption markers showed significant decrease in the 6 th and 12 th months of treatment as compared to values in the control group and values before treatment. |
| first_indexed | 2024-04-10T12:34:24Z |
| format | Article |
| id | doaj.art-af221c2b0a2f4487b63f85576456beae |
| institution | Directory Open Access Journal |
| issn | 2147-2653 |
| language | English |
| last_indexed | 2024-04-10T12:34:24Z |
| publishDate | 2002-03-01 |
| publisher | Galenos Yayinevi |
| record_format | Article |
| series | Türk Osteoporoz Dergisi |
| spelling | doaj.art-af221c2b0a2f4487b63f85576456beae2023-02-15T16:14:46ZengGalenos YayineviTürk Osteoporoz Dergisi2147-26532002-03-01812733The Effect of Alendronate Treatment on Bone Density and Bone Markers in Postmenopausal OsteoporosisS. Akı0R. G. Gulbaba1N. Eskiyurt2İstanbul Tıp Fakültesi Fiziksel Tıp ve Rehabilitasyon Anabilim DalıRIA Labaratuarı, İstanbulİstanbul Tıp Fakültesi Fiziksel Tıp ve Rehabilitasyon Anabilim DalıThe objective of this blind, randomized controlled study was to evaluate effect of 12 months alendronate treatment on bone mineral density (BMD) and bone formation, resorption markers in postmenopausal osteoporotic women. Women with BMD values at least 2 standard deviations (SD) below BMD of adult premenopousal women were included in the study. Patients were randomized into two groups. The control group (n=ll2) received 500 mg daily elemental calcium, while the treatment group (n=l58) received 10 mg alendronate plus 500 mg daily elemental calcium for 12 months. Patient demographics were comparable in both groups before treatment. After 12 months, BMD of patients in alendronate group was increased significantly as compared to BMD before treatment and BMD in control group (p<0.001) . Increase in BMD was apparent in all measured sites but highest values were attained in the Ll-L4 region with 4.8 %. Bone formation and resorption parameters showed significant decrease in the 6 th and 12 th months of treatment as compared to control group and values before treatment (-23.1% to - 50.6 %). As a conclusion, twelve months treatment of alendronate (10 mg/day) in postmenopausal osteoporotic women causes a significant increase of BMD in all measurement sites, as compared to BMD values before treatment and BMD of control group. Likewise bone formation and resorption markers showed significant decrease in the 6 th and 12 th months of treatment as compared to values in the control group and values before treatment.http://www.turkosteoporozdergisi.org/article_4172/The-Effect-Of-Alendronate-Treatment-On-Bone-Density-And-Bone-Markers-In-Postmenopausal-OsteoporosisPostmenopausal osteoporosisalendronatebone mineral densitybone formationresorption markers. |
| spellingShingle | S. Akı R. G. Gulbaba N. Eskiyurt The Effect of Alendronate Treatment on Bone Density and Bone Markers in Postmenopausal Osteoporosis Türk Osteoporoz Dergisi Postmenopausal osteoporosis alendronate bone mineral density bone formation resorption markers. |
| title | The Effect of Alendronate Treatment on Bone Density and Bone Markers in Postmenopausal Osteoporosis |
| title_full | The Effect of Alendronate Treatment on Bone Density and Bone Markers in Postmenopausal Osteoporosis |
| title_fullStr | The Effect of Alendronate Treatment on Bone Density and Bone Markers in Postmenopausal Osteoporosis |
| title_full_unstemmed | The Effect of Alendronate Treatment on Bone Density and Bone Markers in Postmenopausal Osteoporosis |
| title_short | The Effect of Alendronate Treatment on Bone Density and Bone Markers in Postmenopausal Osteoporosis |
| title_sort | effect of alendronate treatment on bone density and bone markers in postmenopausal osteoporosis |
| topic | Postmenopausal osteoporosis alendronate bone mineral density bone formation resorption markers. |
| url | http://www.turkosteoporozdergisi.org/article_4172/The-Effect-Of-Alendronate-Treatment-On-Bone-Density-And-Bone-Markers-In-Postmenopausal-Osteoporosis |
| work_keys_str_mv | AT sakı theeffectofalendronatetreatmentonbonedensityandbonemarkersinpostmenopausalosteoporosis AT rggulbaba theeffectofalendronatetreatmentonbonedensityandbonemarkersinpostmenopausalosteoporosis AT neskiyurt theeffectofalendronatetreatmentonbonedensityandbonemarkersinpostmenopausalosteoporosis AT sakı effectofalendronatetreatmentonbonedensityandbonemarkersinpostmenopausalosteoporosis AT rggulbaba effectofalendronatetreatmentonbonedensityandbonemarkersinpostmenopausalosteoporosis AT neskiyurt effectofalendronatetreatmentonbonedensityandbonemarkersinpostmenopausalosteoporosis |